KOL | Timothy G BergerDepartment of Dermatology, University of California, San Francisco, California, USA | 3University of California at San Francisco, San Francisco, CA, USA | Department of ... |
KOL Resume for Timothy G Berger
| Year | |
|---|---|
| 2021 | Department of Dermatology, University of California, San Francisco, California, USA |
| 2020 | Department of Dermatology, University of California, San Francisco |
| 2019 | Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States. |
| 2017 | Department of Dermatology, University of California San Francisco, San Francisco, CA, USA |
| 2016 | Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco, California |
| 2015 | School of Medicine University of California Department of Dermatology San Francisco CA USA Department of Dermatology, University of California San Francisco |
| 2014 | Department of Dermatology, University of California San Francisco, San Francisco, California |
| 2013 | Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States |
| 2012 | Department of Dermatology, University of California–San Francisco, San Francisco, California |
| 2011 | Department of Dermatology, University of California San Francisco, San Francisco, CA 94143, USA. |
| 2010 | Department of Dermatology at the University of California, San Francisco, San Francisco, California |
| 2009 | Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA |
| 2008 | Department of Dermatology, University of California, San Francisco, San Francisco, California. |
| 2006 | Department of Dermatology, University of California, San Francisco, California, USA. |
| 2005 | Departments of Dermatology University of California, San Francisco and |
| 2004 | From the Department of Dermatology, University of California, San Francisco |
| 2002 | Department of Dermatology, University of California, San Francisco, California, USA, US |
| 2001 | From the WIHS Collaborative Study Group; University of California, San Franciscoa; University of Southern California, Los Angelesb; Mt Sinai Medical Center, New Yorkc; Cook County Hospital, Chicagod; Georgetown University Medical Center, Washingtone; State University of New York Health Science Center at Brooklynf; and Johns Hopkins School of Hygiene and Public Health, Baltimore.g San Francisco and Los Angeles, California; New York and Brooklyn, New York; Chicago, Illinois; Washington, DC; and Baltimore, Maryland |
| 2000 | the Department of Dermatology, San Francisco General Hospital, San Francisco, California, USA University of California Department of Dermatology San Francisco U.S.A. |
| 1999 | San Francisco, California |
| 1998 | Departments of Dermatology, University of California, San Francisco, CA, USA |
| 1997 | From the Departments of Medicine (J.E.K., C.S.G.), Dermatology (M.J.W., T.G.B., P.E.L., J.W.T.), and Pathology (P.E.L.), University of California, San Francisco |
| 1996 | University of California, San Francisco, 400 Parnassus, Box 0316, 94143, San Francisco, CA the Dermatology Service, San Francisco General Hospital, San Francisco, California, USA |
| 1995 | Department of Dermatology, San Francisco General Hospital, San Francisco, California, USA. |
| 1994 | Department of Dermatology, University of California, San Francisco. San Francisco, California, USA |
| 1993 | Department of Dermatology, University of California School of Medicine, San Francisco, CA, USA |
| 1992 | Dermatology Service, Department of Medicine, Letterman Army Medical Center, Presidio, San Francisco, California USA |
| 1991 | Chief, Department of Dermatology, San Francisco General Hospital; and Assistant Clinical Professor of Dermatology, University of California, San Francisco, San Francisco, California |
| 1989 | Departments of Pathology (P.E.L., B.M.E., J.H.B., T.S.B.Y.), Dermatology (P.E.L., T.G.B., B.M.E.), and Laboratory Medicine (J.H.B.), School of Medicine, University of California, San Francisco, California; the Section of Dermatology, San Francisco General Hospital (T.G.B.); and the Department of Pathology and Laboratory Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York (M.H.S.). Department of Dermatology, San Francisco General Hospital, CA. San Francisco General Hospital San Francisco, CA 94110, USA |
| 1988 | From the Dermatology Service, Department of Medicine, Letterman Army Medical Center, Presidio of San Francisco |
| 1987 | From the Dermatology Service Department of Medicine, Letterman Army Medical Center, Presidlo of San Francisco, CA San Francisco, USA Dermatology Service, Department of Medicine, Letterman Army Medical Center, U.S.A. |
| 1986 | Dermatology Service, Department of Medicine, Letterman Army Medical Center, Presidio of San Francisco, California |
| 1985 | the Dermatology Service, Letterman Anny Medical Center, Presidio of San Francisco, CA |
| 1984 | Armed Forces Institute of Pathology and the Veterans Administration Special Reference Laboratory for Pathology, Washington, DC San Francisco, CA, USA |
Timothy G Berger: Influence Statistics
| Concept | World rank |
|---|---|
| keloidalis nuchae keloidalis | #1 |
| lesions kaposi | #1 |
| reported cases mtx | #1 |
| healthcare behaviors elements | #1 |
| entities bullosa | #1 |
| 13 hivseropositive patients | #1 |
| undiversion patient | #1 |
| helper tcell count | #1 |
| patients lichenoid eruptions | #1 |
| ederm clerkship | #1 |
| dermatology clinics university | #1 |
| dermatology clerkship | #1 |
| clinical photodermatitis | #1 |
| center dermatology clinics | #1 |
| hivinfected patients mtx | #1 |
| rediversion entities | #1 |
| prp rubra pilaris | #1 |
| lichenoid photoeruptions | #1 |
| uvb 13 patients | #1 |
| psoralen uva exhibit | #1 |
| 12 acquired | #1 |
| dideoxyinosine sulfamethoxazole | #1 |
| pruritus elderly patients | #1 |
| photodermatitis native ancestry | #1 |
| eventual pigmentation | #1 |
| medications dideoxyinosine | #1 |
| thalidomide 100 subjects | #1 |
| subsequent immune restoration | #1 |
| neurological interactions | #1 |
| pruritus evidence review | #1 |
| hyperpigmentation inbred c57bl | #1 |
| ederm | #1 |
| dermatologists diagnose | #1 |
| tpn neuropathy | #1 |
| hivassociated pruritus | #1 |
| hiv diseases treatment | #1 |
| aad online curriculum | #1 |
| diagnosis ederm | #1 |
| students perceptions usability | #1 |
| selective hyperpigmentation | #1 |
| background bacillary | #1 |
| reported cases polychondritis | #1 |
Open the FULL List in Excel | |
Prominent publications by Timothy G Berger
Identification of herpes simplex virus DNA in lesions of erythema multiforme by the polymerase chain reaction
[ PUBLICATION ]
An association between erythema multiforme and herpes simplex virus infection has been supported by clinical studies and by the detection by immunofluorescence of herpes viral antigen in sera and skin biopsy specimens of patients with erythema multiforme. In rare cases, the virus has also been isolated in cultures of skin biopsy specimens of erythema multiforme. To investigate further the association between erythema multiforme and herpes simplex virus, we used the polymerase chain ...
| Known for Simplex Virus | Erythema Multiforme | Polymerase Chain Reaction | Viral Dna | Skin Lesions |
The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics. ...
| Known for Mohs Surgery | Situ Carcinoma | Dermatology College | Basal Cell | Evidencebased Medicine |
Molecular Epidemiology of Bartonella Infections in Patients with Bacillary Angiomatosis–Peliosis
[ PUBLICATION ]
BACKGROUND: Bacillary angiomatosis and bacillary peliosis are vascular proliferative manifestations of infection with species of the genus bartonella that occur predominantly in patients infected with the human immunodeficiency virus. Two species, B. henselae and B. quintana, have been associated with bacillary angiomatosis, but culture and speciation are difficult, and there has been little systematic evaluation of the species-specific disease characteristics. We studied 49 patients ...
| Known for Molecular Epidemiology | Bartonella Infections | Henselae Quintana | Patients Bacillary Angiomatosis | Bacillary Peliosis |
Isolation of Rochalimaea Species from Cutaneous and Osseous Lesions of Bacillary Angiomatosis
[ PUBLICATION ]
BACKGROUND: Bacillary angiomatosis is characterized by vascular lesions, which occur usually in patients infected with the human immunodeficiency virus (HIV). A newly described gram-negative organism, Rochalimaea henselae, has been associated with cutaneous bacillary angiomatosis, but no organism has been isolated and cultivated directly from cutaneous tissue.
METHODS: We used two methods to isolate the infecting bacterium from four HIV-infected patients with cutaneous lesions suggestive ...
| Known for Bacillary Angiomatosis | Rochalimaea Species | Patients Quintana | Cutaneous Lesions | Blood Patient |
Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review
[ PUBLICATION ]
IntroductionIntense nocturnal pruritus as well as the complex pathophysiology of atopic dermatitis (AD) can severely affect sleep and become a major factor in negatively impacting quality of life in adults. However, much of the literature on sleep disturbance in AD patients is on the pediatric population, and it is not well studied in adults. Furthermore, limited studies are available to guide effective management of sleep disturbance in AD in general. We review the literature to present ...
| Known for Sleep Disturbance | Adults Atopic Dermatitis | Major Factor | Effective Management | Disease Control |
Objective: To examine risk factors for the development of cutaneous squamous cell carcinoma (SCC) in a group of human immunodeficiency virus (HIV)— infected patients, including evaluation and detection of epidemiologic risk factors of human papillomavirus (HPV) and p53 expression.Design: Case-control study during a 3-year period.Setting: Dermatologic referral center.Patients: Thirty-three HIV-infected patients who had 97 SCCs were compared with 24 HIV-infected patients who had 70 basal ...
| Known for Human Papillomavirus | Cell Carcinoma | Hivinfected Patients | Immunodeficiency Virus | Cutaneous Squamous |
Background and Design: This study determines (1) the readiness of primary care physicians (PCPs) to triage optimally lesions suspicious for skin cancer, (2) the difference in their abilities from those of dermatologists, and (3) whether accurate diagnosis after viewing slide images transfers to accurate diagnosis after viewing lesions on patients. Seventy-one primary care residents and 15 dermatologists and resident dermatologists diagnosed and selected a treatment/diagnostic plan for ...
| Known for Skin Cancer | Primary Residents | Accurate Diagnosis | Malignant Melanomas | Lesions Dermatologists |
Thalidomide Treatment for Prurigo Nodularis in Human Immunodeficiency Virus –Infected Subjects: Efficacy and Risk of Neuropathy
[ PUBLICATION ]
OBJECTIVE: To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment.
DESIGN: Prospective study.
SETTING: Outpatient dermatology and neurology clinic, both referral settings.
PATIENTS: Eight HIV-infected patients with refractory prurigo nodularis; a total of 10 met inclusion criteria, but 2 could not be followed up.
INTERVENTIONS: Treatment ...
| Known for Prurigo Nodularis | Thalidomide Treatment | Human Immunodeficiency Virus | Peripheral Neuropathy | Immunosuppressive Agents |
Certain skin cancers occur with increased frequency or altered course in patients infected with HIV. Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV. Others, such as basal cell carcinoma, appear more frequently in this population but do not appear to be more aggressive. The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy. Our ...
| Known for Cutaneous Malignancy | Anaplastic Lymphoma | Basal Cell Carcinoma | Patients Hiv | Skin Cancers |
Kaposi's sarcoma Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy
[ PUBLICATION ]
The acquired immunodeficiency syndrome (AIDS) epidemic has had a profound impact on our understanding of Kaposi's sarcoma (KS). Epidemiologic features suggest a sexually transmitted cofactor in the pathogenesis of AIDS-associated KS (AIDS-KS), and several putative agents have received intense scrutiny. Cell culture studies suggest that the angiogenesis of AIDS-KS is stimulated by both human immunodeficiency virus proteins and growth factors that may be involved in the development and ...
| Known for Clinical Spectrum | Ks Patients | Local Therapy | Sarcoma Kaposi | Cutaneous Lesions |
Key People For Bacillary Angiomatosis
Timothy G Berger:Expert Impact
Concepts for whichTimothy G Bergerhas direct influence:Bacillary angiomatosis, Atopic dermatitis, Human immunodeficiency virus, Human papillomavirus, Hiv infection, Skin cancer, Herpes simplex virus, Patients aids.
Timothy G Berger:KOL impact
Concepts related to the work of other authors for whichfor which Timothy G Berger has influence:Atopic dermatitis, Bacillary angiomatosis, Hiv infection, Bartonella henselae, Skin cancer, Kaposi sarcoma, Scratch disease.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |